Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
1 hedge funds and large institutions have $72 invested in Adaptimmune Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 9 closing their positions.
0.63% less ownership
Funds ownership: 0.63% → 0% (-0.63%)
90% less funds holding
Funds holding: 10 → 1 (-9)
100% less capital invested
Capital invested by funds: $79.7K → $72 (-$79.6K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 9
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAIC
Josh Arnold Investment Consultant
Edina,
Minnesota
|
-$37.8K |
| 2 |
EF
Empirical Finance
Havertown,
Pennsylvania
|
-$20.8K |
| 3 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
-$11.3K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$9.2K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$483 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
RhumbLine Advisers
Boston,
Massachusetts
| $72 | – | – | – |
|
|
EF
2
Empirical Finance
Havertown,
Pennsylvania
| – | -$20.8K | -800,000 | Closed |
|
|
RG
3
Rathbones Group
Liverpool,
United Kingdom
| – | -$11.3K | -432,818 | Closed |
|
|
XT
4
XTX Topco
George Town,
Cayman Islands
| – | -$9.2K | -353,836 | Closed |
|
|
JAIC
5
Josh Arnold Investment Consultant
Edina,
Minnesota
| – | -$37.8K | -20,000 | Closed |
|
|
6
Simplex Trading
Chicago,
Illinois
| – | -$483 | -18,610 | Closed |
|
7
Barclays
London,
United Kingdom
| – | -$66 | -2,532 | Closed |
|
ADAP Hedge Fund Activity: Q1 2026 in Review
1 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2026, worth a combined $72 — down 100% from $79.7K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ADAP and 0 opened new positions — a net loss of 9 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Josh Arnold Investment Consultant, exiting entirely with an estimated $37.8K sold.
- 1 institutional investor held Adaptimmune Therapeutics (ADAP) as of Q1 2026, down from 10 in Q4 2025.
- Funds reported $72 of Adaptimmune Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Adaptimmune Therapeutics positions in Q1 2026 and 9 closed out, a net change of -9 holders.
- The largest Adaptimmune Therapeutics seller in Q1 2026 was Josh Arnold Investment Consultant, an estimated $37.8K sold.
Based on aggregated 13F filings for Q1 2026.